Neximmune presents initial positive data from the nexi-001 phase 1 trial for relapsed/refractory post allo-hsct aml at the american society of clinical oncology 2023 annual meeting

- trial includes high risk aml patients that have relapsed post allo-hsct and are refractory to salvage therapy - nexi-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of may 2023 - robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with nexi-001 - antigen-specific t cells persist in blood and bone marrow and maintain important phenotypes that are associated with anti-tumor effect and immunologic memory gaithersburg, md., june 05, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells for liquid and solid malignancies, today announced results from its phase 1/2 clinical trial of nexi-001 in patients with relapsed/refractory acute myeloid leukemia (aml) post-allogeneic hemopoietic stem cell transplant (allo-hsct).
NEXI Ratings Summary
NEXI Quant Ranking